The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $147.96

Today's change-3.82 -2.52%
Updated September 1 10:24 AM EDT. Delayed by at least 15 minutes.
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $147.96

Today's change-3.82 -2.52%
Updated September 1 10:24 AM EDT. Delayed by at least 15 minutes.

Amgen Inc down (U.S.)$3.82

Amgen Inc is sharply lower today, dropping (U.S.)$3.82 or 2.52% to (U.S.)$147.96. Over the last five days, shares have gained 1.91%, but are down 7.11% for the last year to date. Shares have outperformed the S&P 500 by 9.83% during the last year.

Key company metrics

  • Open(U.S.) $149.23
  • Previous close(U.S.) $151.78
  • High(U.S.) $150.99
  • Low(U.S.) $147.65
  • Bid / Ask(U.S.) $147.80 / (U.S.) $148.03
  • YTD % change-7.11%
  • Volume1,282,992
  • Average volume (10-day)5,267,141
  • Average volume (1-month)3,899,435
  • Average volume (3-month)3,553,212
  • 52-week range(U.S.) $127.67 to (U.S.) $181.81
  • Beta0.61
  • Trailing P/E19.60×
  • P/E 1 year forward15.58×
  • Forward PEG1.30×
  • Indicated annual dividend(U.S.) $3.16
  • Dividend yield2.14%
  • Trailing EPS(U.S.) $7.55
Updated September 1 10:24 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+28.00%

Based on its net profit margin of 28.00%, Amgen Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue5,3705,0335,3315,031
Total other revenue--------
Total revenue5,3705,0335,3315,031
Gross profit4,2814,0004,1484,162
Total cost of revenue1,0891,0331,183869
Total operating expense3,2943,0113,8723,565
Selling / general / administrative1,1601,0261,3271,213
Research & development9648941,2341,018
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)81--9529
Other operating expenses, total--58119-64
Operating income2,0762,0221,4591,466
Interest income (expense), net non-operating-277-252-261-269
Gain (loss) on sale of assets--------
Other--------
Income before tax1,9971,8761,2861,337
Income after tax1,6531,6231,2941,244
Income tax, total344253-893
Net income1,6531,6231,2941,244
Total adjustments to net income--------
Net income before extra. items1,6531,6231,2941,244
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,6531,6231,2941,244
Inc. avail. to common incl. extra. items1,6531,6231,2941,244
Diluted net income1,6531,6251,2941,244
Dilution adjustment--2--0
Diluted weighted average shares768770773771
Diluted EPS excluding extraordinary itemsvalue per share2.152.111.671.61
Dividends per sharevalue per share0.790.790.610.61
Diluted normalized EPSvalue per share2.242.111.682.25